Trexall Tablet, Film Coated
Pricing Report NDC 51285-367-01
Current Package Pricing Information
The current wholesale acquisition cost for Trexall (NDC 51285-367-01) is $36.20914 per EA. This benchmark price is based on the National Average Drug Acquisition Cost (NADAC) and has been effective since Feb 18, 2026.
As a a human prescription drug provided by Teva Women's Health Llc, this medication is distributed in a 30 TABLET, FILM COATED in 1 BOTTLE configuration. The pricing data is derived from C/I - Chain or Independent Pharmacy surveys, reflecting the actual invoice prices paid by community pharmacies to drug wholesalers.
NADAC Pricing Summary
NADAC pricing snapshot for this package NDC
Acquisition Cost $36.20914 Per EA
The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation.
Historical Pricing Trends & Acquisition Cost Benchmarks
Since Feb 2026, the NADAC wholesale price for (NDC ) has moved within a range of $36.20914 to $36.20914 per EA. Over this the last few weeks period, the pricing trend reflects the shifting acquisition costs reported by retail and chain pharmacies to the Centers for Medicare and Medicaid Services (CMS). The following interactive chart and historical table detail every recorded price adjustment based on these federal surveys.
| Date | Unit Price | Unit | Source | Method | Rate |
|---|---|---|---|---|---|
| Feb 18, 2026 | $36.20914 | EA | C/I - Chain or Independent Pharmacy | Code 3, 6 | B-ANDA - Abbreviated New Drug Application |
| Feb 18, 2026 | $36.20914 | EA | C/I - Chain or Independent Pharmacy | Code 4, 6 | B-ANDA - Abbreviated New Drug Application |
Pricing Methodology Legend
- Code 3: The NADAC based on survey data has been adjusted to reflect changes in published pricing, or as a result of an inquiry to the help desk.
- Code 4: The NADAC was carried forward from the previous file.
- Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation.
Understanding NADAC Pricing Data
The National Average Drug Acquisition Cost (NADAC) is compiled by the Centers for Medicare and Medicaid Services (CMS). This data is derived from random monthly surveys of more than 60,000 pharmacies across all 50 states.
Important Price Distinction:
The prices listed on this page represent the wholesale invoice price paid by pharmacies to acquire the drug. This is NOT the retail price paid by consumers at the pharmacy counter. Final patient costs typically include pharmacy markups, professional dispensing fees, and insurance adjustments.
NADAC Pricing Data Last Updated on: July 08, 2026
